The UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (UK CERSI-PGx), led by the University of Liverpool, has published its first clinical guideline focused on the use of the antiplatelet medication clopidogrel, widely prescribed in the UK to prevent blood clots. Pharmacogenomics looks at how differences in our genes can change the way medicines affect each person.
The guideline addresses CYP2C19 genotyping in patients prescribed clopidogrel for conditions such as coronary artery disease, cerebrovascular disease, and peripheral arterial disease. This is because clopidogrel does not work uniformly in all patients.
CYP2C19 is an enzyme in the liver that influences how clopidogrel is converted in the body into its active form. Different people have different levels of this enzyme because of variation in their CYP2C19 gene. Those with low enzyme levels will activate clopidogrel less efficiently than those with “normal” levels making clopidogrel less effective— this variability can be detected by a simple genetic test. A significant proportion of the population have lower enzyme levels: in white individuals it is 20-30%, but it can be as high as 50-60% in those of Asian descent.
Rather than duplicating existing international pharmacogenomic guidelines from CPIC and DPWG, the UK CERSI-PGx guideline provides a greater clinical focus, offering practical recommendations on:
- Eligibility for testing
- Integration into current clinical pathways
- Variants to test and turnaround times
- Actions based on genotype
- Health economic considerations
- Evidence gaps and future research priorities
The development of these guidelines is a first for the UK and has been undertaken by a committee with a representative group of specialists. These guidelines will be important for regulators, for industry and for the NHS. The NHS 10-year plan states that “pharmacogenomics will be integrated into routine clinical practice” – the current guideline, and the others which are currently in development by CERSI-PGx, will help with that ambition.
UK CERSI-PGx is funded by Innovate UK and the Medical Research Council, in conjunction with the MHRA, as part of the UK’s network of seven Centres of Excellence for Regulatory Science and Innovation. Collaborators in CERSI-PGx include The University of Manchester, Queen Mary University of London, Bangor University, The Office of Health Economics, The British Pharmacological Society, JS O’Brien Business Solutions, and Alderley Lighthouse Labs.
Centre Lead the University of Liverpool’s Professor Sir Munir Pirmohamed said: “With the new CERSI-PGx guideline for clopidogrel, we aim to ensure patients are prescribed the right treatment at the right dose, based on their genetics. By integrating CYP2C19 testing into routine pathways, we can improve efficacy, reduce adverse drug reactions, ease pressure on the NHS, and support cost-effective, precision prescribing.”
MHRA’s Chief Safety Officer, Dr Alison Cave, said: “This first clinical guideline from UK-CERSI-PGx for clopidogrel provides practical recommendations to accelerate the integration of pharmacogenomics into routine care. By analysing a patient’s genetic information, pharmacogenomics ensures they receive the most appropriate medication and dosage for their specific genetic profile minimising the risk of adverse drug reactions. Such approaches form part of MHRA’s long-term vision for more personalised medicine prescribing and will be a gamechanger for patient safety and wellbeing.”
The guidelines and a related editorial are published today (4 December 2025) in the British Journal of Clinical Pharmacology.
Ends
Subject of Research
People
Article Publication Date
4-Dec-2025